Comparison of diagnostic methodologies to detect chromosomal abnormalities. Read more about Comparison of diagnostic methodologies to detect chromosomal abnormalities.
Pro-Tumorigenic Mechanisms of M2 Tumor-Associated Macrophages in Triple-Negative Breast Cancer Read more about Pro-Tumorigenic Mechanisms of M2 Tumor-Associated Macrophages in Triple-Negative Breast Cancer
Characterization of TIGIT Expression Using MultiOmyx™ Hyperplexed Immunofluorescence Assay in NSCLC and melanoma Read more about Characterization of TIGIT Expression Using MultiOmyx™ Hyperplexed Immunofluorescence Assay in NSCLC and melanoma
Using a Multiplexed Immunofluorescence Approach to Compare Immune Cell Populations in Subtypes on Non-Small Cell Lung Cancer Read more about Using a Multiplexed Immunofluorescence Approach to Compare Immune Cell Populations in Subtypes on Non-Small Cell Lung Cancer
An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors Read more about An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors
An Integrated Multiplexing Approach Identifies IDO1 as a Biomarker for Recurrence of Rare Ovarian Granulosa Cell Tumors Read more about An Integrated Multiplexing Approach Identifies IDO1 as a Biomarker for Recurrence of Rare Ovarian Granulosa Cell Tumors
A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2- breast cancer patients using and FDA TR-PCR cleared test3 Read more about A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2- breast cancer patients using and FDA TR-PCR cleared test3
Phenotypic Characterization of the Immune Landscape in the Bone Marrow of Patients with Acute Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence Assay Read more about Phenotypic Characterization of the Immune Landscape in the Bone Marrow of Patients with Acute Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence Assay
PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors Read more about PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues Read more about Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues